Navigation Links
Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
Date:12/3/2008

GOTHENBURG, Sweden, December 3 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the signing of a collaborative agreement with The Automation Partnership (TAP) in the UK, manufacturers of advanced automated systems for cell culture, sample management and high throughput screening applications. Under the agreement TAP will co-develop and manufacture the Dynaflow(R)HT System, Cellectricon's next generation high throughput ion channel screening platform. Dynaflow(R)HT will be launched and commercially available in 2009.

Addressing the limitations of current ion channel screening technologies, the Dynaflow(R)HT yields an unmatched level of automated throughput while still delivering unique measurement data quality. The concept and technology has been developed and validated over the last three years by Cellectricon in partnership with AstraZeneca.

"We are excited to partner with TAP who are world-renowned for manufacturing industrial quality automation," says Jonas Ohlsson, CEO at Cellectricon. "To bring this fully automated state-of-the-art high throughput electrophysiology system to the market is a milestone for ion channel screening. The system offers unmatched throughput, cost per data point and reliability/predictability."

"The Automation Partnership (TAP) are very pleased to have the opportunity to work with Cellectricon in automating their unique high throughput microfluidic screening platform," says Andy Morffew Chief Executive Officer. "We are looking forward to supporting this system with a wide range of excellent technical and professional services, designed to ensure customers gain optimum return from their capital investment."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. In 2007, the company increased its annual revenue by almost 50%. In 2008-2009 the company is launching two pioneering large-scale screening platforms developed in close collaboration with leaders in the pharmaceutical industry. Used in pre-clinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput RNAi screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

About The Automation Partnership

The Automation Partnership (TAP) is a world leader in the design, development and implementation of advanced automation systems for the life sciences research industry. TAP specializes in automation for cell culture, sample management and advanced screening applications. These range from multi-million pound large-scale drug discovery facilities to standalone bench-top products. TAP also offers custom engineering services to customers requiring unique solutions for complex and challenging research problems.

TAP's customers include the world's top pharmaceutical and biotechnology companies, key service providers and leading research institutions including: Amgen, AstraZeneca, ATCC, GlaxoSmithKline, Loughborough University, Max Planck Institute, Merck, Oxford University, Stem Cell Sciences, UK Biobank and Wyeth.

    Contact Cellectricon:

    Jonas Ohlsson, CEO
    Phone: +46(0)709-73-47-92
    E-mail: jonas.ohlsson@cellectricon.com

    Susanne Fagerlund, VP Marketing & Communications
    Phone: +46(0)31-760-35-15
    Email: susanne.fagerlund@cellectricon.com

    Contact The Automation Partnership:

    Matthew Walker, Head of Communications
    Phone: +44(0)1763-22-72-00
    E-mail: matthew.walker@automationpartnership.com


'/>"/>
SOURCE Cellectricon AB
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... SPRING, Md. , June 23, 2016 A ... collected from the crime scene to track the criminal down. ... and the U.S. Food and Drug Administration (FDA) uses DNA ... Sound far-fetched? It,s not. The ... genome sequencing to support investigations of foodborne illnesses. Put as ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology:
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):